Truist initiated coverage of Septerna (SEPN) with a Buy rating and $34 price target The firm says the company’s SEP-631 is in Phase 1 for chronic spontaneous urticaria and presents novel oral option for a multi-billion market opportunity. The firm views the data in the first half of 2026 as a key catalyst for the shares.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SEPN: